Lv22
116 积分 2022-05-13 加入
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer
2小时前
待确认
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
1天前
已完结
Clearer Horizons: The latest advances in clear cell ovarian cancer treatment
1天前
已完结
PPP2R1A mutations portend improved survival after cancer immunotherapy
15天前
已完结
New horizons at the interface of artificial intelligence and translational cancer research
1个月前
已完结
Secondary Cytoreductive Surgery for Ovarian Cancer With Second Platinum‐Sensitive Recurrence: A Multicentre Retrospective Cohort Study
1个月前
已关闭
Secondary Cytoreductive Surgery for Ovarian Cancer With Second Platinum‐Sensitive Recurrence: A Multicentre Retrospective Cohort Study
1个月前
已关闭
Combination of PARP Inhibitor and Antiangiogenic Therapy Following Disease Progression in Patients With Epithelial Ovarian Cancer Undergoing PARP Inhibitor Maintenance Therapy: A Real‐World Study
1个月前
已完结
Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
2个月前
已完结
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2个月前
已完结
皖公网安备34019202002308
